With a growing range of new vaccines coming on to the market and evidence that some countries simply could not sustain the significant increases in funding required to maintain immunisation programmes, Gavi's first-ever strategy incorporated a detailed review of how best to deploy its growing resources:

STRATEGIC GOALS

Four strategic goals underpinned Phase II

Strategic Goal 1

Contribute to the strengthening the capacity of the health system to deliver immunisation and other health services in a sustainable manner

Contribute to the strengthening the capacity of the health system to deliver immunisation and other health services in a sustainable manner

Strategic Goal 2

Accelerate the uptake and use of underused and new vaccines and associated technologies and improve vaccine supply security

Accelerate the uptake and use of underused and new vaccines and associated technologies and improve vaccine supply security

Strategic Goal 3

Increase the predictability and sustainability of long-term financing for national immunisation programmes

Increase the predictability and sustainability of long-term financing for national immunisation programmes

Strategic Goal 4 

Increase and assess the added value of Gavi as a public-private global health partnership through improved efficiency, increased advocacy and continued innovation

Increase and assess the added value of Gavi as a public-private global health partnership through improved efficiency, increased advocacy and continued innovation

WORKPLAN, ACTIVITIES, OUTPUTS

With a total budget of US$ 297 million available for the strategy's four-year life cycle, any given year in the Gavi strategy contained up to 100 activities. To help measure progress, these activities are reported against 17 outputs.

The 2010 Work Plan Report highlights the 2010 progress under each output. It is based on the reporting provided by WHO, UNICEF, World Bank, AVI TAC and the Gavi Secretariat. The paper includes an annex table summarising the progress per output against the 2010 work plan targets.

Related downloads

Latest news

19 January 2022

World leaders launch call for renewed support for vaccination in 2022 as part of the global fight against COVID-19

COVAX, the vaccine pillar of the Access to COVID-19 Tools Accelerator (ACT-Accelerator), has now shipped over 1 billion doses to 144 countries and territories.

21 December 2021

COVAX awarded 2021 North-South Prize for enhancing global equitable access to COVID-19 vaccines

Geneva, 21 December 2021 – The COVAX Facility has been awarded the 2021 North-South Prize of the Council of Europe in recognition of its efforts to ensure that COVID-19 vaccines are available worldwide, including in low-income countries, and for…

10 December 2021

Gavi and Moderna reach agreement for additional supply to COVAX

Agreement will make up to an additional 150 million doses of the Moderna COVID-19 vaccine available to COVAX Facility participants in Q2 and Q3 2022, at the lowest tiered price.

Last updated: 14 Jan 2020

Subscribe to our newsletter